347 related articles for article (PubMed ID: 25751641)
1. Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.
Zhang X; Xin L; Li S; Fang M; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2015; 11(5):1277-92. PubMed ID: 25751641
[TBL] [Abstract][Full Text] [Related]
2. Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
Simanavicius M; Tamosiunas PL; Petraityte-Burneikiene R; Johne R; Ulrich RG; Zvirbliene A; Kucinskaite-Kodze I
Appl Microbiol Biotechnol; 2018 Jan; 102(1):185-198. PubMed ID: 29143081
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
4. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
[TBL] [Abstract][Full Text] [Related]
5. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
Zhang X; Wei M; Pan H; Lin Z; Wang K; Weng Z; Zhu Y; Xin L; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2014 Jul; 32(32):4039-50. PubMed ID: 24892250
[TBL] [Abstract][Full Text] [Related]
6. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
7. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
Joshi H; Lewis K; Singharoy A; Ortoleva PJ
Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
Módolo DG; Araldi RP; Mazzuchelli-de-Souza J; Pereira A; Pimenta DC; Zanphorlin LM; Beçak W; Menossi M; de Cassia Stocco R; de Carvalho RF
Vaccine; 2017 Mar; 35(12):1590-1593. PubMed ID: 28222997
[TBL] [Abstract][Full Text] [Related]
9. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
[TBL] [Abstract][Full Text] [Related]
10. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.
Xia L; Xian Y; Wang D; Chen Y; Huang X; Bi X; Yu H; Fu Z; Liu X; Li S; An Z; Luo W; Zhao Q; Xia N
Sci Rep; 2016 Jan; 6():19042. PubMed ID: 26750243
[TBL] [Abstract][Full Text] [Related]
11. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
12. Lessons from hepatitis E vaccine design.
Li S; Zhang J; Xia N
Curr Opin Virol; 2015 Apr; 11():130-6. PubMed ID: 25913817
[TBL] [Abstract][Full Text] [Related]
13. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
14. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
15. Meeting report VLPNPV: Session 8: Vaccines I.
Thiriot DS
Hum Vaccin Immunother; 2014; 10(10):3078-9. PubMed ID: 25483643
[TBL] [Abstract][Full Text] [Related]
16. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
Wei M; Zhang X; Yu H; Tang ZM; Wang K; Li Z; Zheng Z; Li S; Zhang J; Xia N; Zhao Q
Vaccine; 2014 May; 32(24):2859-65. PubMed ID: 24662711
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation.
Li Y; Huang X; Zhang Z; Li S; Zhang J; Xia N; Zhao Q
Viruses; 2020 Jan; 12(1):. PubMed ID: 31963175
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties.
Zhao Q; Li S; Yu H; Xia N; Modis Y
Trends Biotechnol; 2013 Nov; 31(11):654-63. PubMed ID: 24125746
[TBL] [Abstract][Full Text] [Related]
20. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
Eto Y; Saubi N; Ferrer P; Joseph J
AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
